Boston Scientific Acquires Axonics for $3.7 Billion

Deal gives Boston Scientific access to devices treating urinary and bowel disorders, impacting millions of Americans.

Boston Scientific Corp. has agreed to buy medical technology firm Axonics Inc. for $3.7 billion in cash, or $71 a share, which is a 23% premium on Axonics' closing price last Friday.
The acquisition will give Boston Scientific access to Axonics' product portfolio, which includes a device that delivers electrical stimulation to restore communication between the brain and the bladder.
Nearly 30 million Americans aged 40 and older have symptoms of overactive bladder and another 19 million adults have fecal incontinence, conditions that Axonics' products can help treat.
The purchase is not expected to materially impact Boston Scientific’s 2024 adjusted earnings per share, but it will add to them thereafter.
Axonics' stock rose 22% in pre-market trading following the announcement, while Boston Scientific's stock remained largely unchanged.